Expert Opin Investig Drugs. 2013 Nov;22(11):1365-70. doi: 10.1517/13543784.2013.841137. Epub 2013 Oct 7.

Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity.

Reikvam H, Nepstad I, Tamburini J.

Cell Prolif. 2013 Oct;46(5):554-62. doi: 10.1111/cpr.12057.

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients.

Reikvam H, Øyan AM, Kalland KH, Hovland R, Hatfield KJ, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Jun;4(6):830-43.

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.

Reikvam H, Nepstad I, Bruserud Ø, Hatfield KJ.

Transfus Med. 2013 Dec;23(6):397-406. doi: 10.1111/tme.12067. Epub 2013 Aug 6.

Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia.

Bruserud O, Liseth K, Stamnesfet S, Cacic DL, Melve G, Kristoffersen E, Hervig T, Reikvam H.

Clin Epigenetics. 2013 Aug 1;5(1):13. doi: 10.1186/1868-7083-5-13.

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.

Fredly H, Ersvær E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O.

Clin Epigenetics. 2013 Jul 30;5(1):12. doi: 10.1186/1868-7083-5-12.

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.

Fredly H, Gjertsen BT, Bruserud O.

BMC Pharmacol Toxicol. 2013 Jul 11;14:35. doi: 10.1186/2050-6511-14-35.

Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.

Bredholt T, Ersvær E, Erikstein BS, Sulen A, Reikvam H, Aarstad HJ, Johannessen AC, Vintermyr OK, Bruserud Ø, Gjertsen BT.

Cytotherapy. 2013 Apr 24. pii: S1465-3249(13)00409-X. doi: 10.1016/j.jcyt.2013.02.008. [Epub ahead of print]

Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma.

Mosevoll KA, Akkök CA, Hervig T, Melve GK, Bruserud O, Reikvam H.

Expert Opin Investig Drugs. 2013 May;22(5):551-63. doi: 10.1517/13543784.2013.791280.

Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.

Reikvam H, Nepstad I, Sulen A, Gjertsen BT, Hatfield KJ, Bruserud Ø.

Oncoimmunology. 2013 Feb 1;2(2):e23138.

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Sand KE, Rye KP, Mannsåker B, Bruserud O, Kittang AO.

Cell Death Dis. 2013 Feb 28;4:e516. doi: 10.1038/cddis.2013.39.

Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.

Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO.

Blood. 2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555. Epub 2012 Dec 12.

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.

McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT.

Oncoimmunology. 2013 Feb 1;2(2):e23138.

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Sand KE, Rye KP, Mannsåker B, Bruserud O, Kittang AO.

Toxins (Basel). 2013 Feb 18;5(2):336-62. doi: 10.3390/toxins5020336.

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation.

Reikvam H, Fredly H, Kittang AO, Bruserud O.

Mar Drugs. 2013 Jan 30;11(2):332-49. doi: 10.3390/md11020332.

Iodinin (1,6-Dihydroxyphenazine 5,10-Dioxide) from Streptosporangium sp. Induces Apoptosis Selectively in Myeloid Leukemia Cell Lines and Patient Cells.

Myhren LE, Nygaard G, Gausdal G, Sletta H, Teigen K, Degnes KF, Zahlsen K, Brunsvik A, Bruserud O, Døskeland SO, Selheim F, Herfindal L.

Curr Cancer Drug Targets. 2013 Jan;13(1):30-47.

Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?

Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud Ø.